Balancing act for new drugs


Candy Chen and Vivian Chen

Protecting the intellectual property of new drugs is complicated but essential for pharmaceutical companies. Patents are important in this respect, but by themselves they do not always create a sufficiently favourable environment for encouraging drug development.

Patent, FDA, NME, Taiwanese Pharmaceutical Affairs Act, Hatch-Waxman Act, pharmaceuticals